|Last Update: 06/19/13 - 3:30 PM EDT|
|YTD Performance: 32.39%|
|Previous Close: $34.54|
|52 Week Range: $20.49 - $35.02|
|Oustanding Shares: 444,646,972|
|Market Cap: 15,273,623,488|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||14||13||16||16|
|Growth Rate (Year over Year)||26.13%||29.49%||12.37%||16.07%|
Shares of IVZ were downgraded to Neutral from Buy, said UBS. Progress toward margin target has been solid and is priced in. Price target goes to $35.
IVZ earnings estimates were increased as stronger cost controls are expected to lead to margin expansion, said Citigroup. Price target goes to $39.
IVZ was added to Top Picks Live! at Citigroup. $34 price target. Deep YTD underpeformance.
IVZ was downgraded from Outperform to Market Perform, BMO Capital said. Valuation call, based on a $29 price target.
IVZ was downgraded from Overweight to Equal-weight, Morgan Stanley said. $30 price target. Company lacks near-term catalysts.
Shares of IVZ now seen reaching $27.50, Citigroup said. Estimates also lowered as October AUM in line, but equities remain sluggish.
Shares of IVZ now seen reaching $28, according to BMO Capital. Estimates also increased, as the company is gaining market share.
IVZ estimates were cut through 2013, BMO Capital said. Company is hurt by lower market performance and currency headwinds. Outperform rating and new $27 price target.
Shares of IVZ now seen reaching $30, according to Citigroup. Estimates also increased as model efficacy climbs and risks dissipate. Buy rating.
Shares of IVZ now seen reaching $26, according to Credit Suisse. Estimates also upped, as the company is carrying a lot of earnings momentum into the new year. Outperform rating.